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Abstract
Introduction Candida albicans and Candida glabrata are
the two most common opportunistic pathogens which are part
of the normal flora in humans. Clinical diagnosis of infection
by these organisms is still largely based on culturing of these
organisms. In order to identify species-specific protein
expression patterns, we carried out a comparative proteomic
analysis of C. albicans and C. glabrata.
Methods We used “isobaric tag for relative and absolute
quantitation” (iTRAQ) labeling of cell homogenates of C.
albicans and C. glabrata followed by LC-MS/MS analysis
using a quadrupole time-of-flight mass spectrometer. The
MS/MS data was searched against a protein database
comprised of known and predicted proteins reported from
these two organisms. Subsequently, we carried out a
bioinformatics analysis to group orthologous proteins
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across C. albicans and C. glabrata and calculated protein
abundance changes between the two species.
Results and Conclusions We identified 500 proteins from
these organisms, the large majority of which corresponded to
predicted transcripts. A number of proteins were observed to
be significantly differentially expressed between the two
species including enolase (Eno1), fructose-bisphosphate
aldolase (Fba1), CCT ring complex subunit (Cct2), pyruvate
kinase (Cdc19), and pyruvate carboxylase (Pyc2). This study
illustrates a strategy for investigating protein expression
patterns across closely related organisms by combining
orthology information with quantitative proteomics.
Keywords Biomarker . Candidiasis . Candidemia .Medical
mycology .Molecular diagnostics . Fungal infection .
Quantitative proteomics
Abbreviations
MTCC Microbial type culture collection
ORF Open reading frame
Introduction
Candida albicans and Candida glabrata are the commonest
opportunistic pathogens of human mucosa and blood [1–3].
Clinical disorders with immunosuppression including those
with HIV and patients on chemotherapy provide an
opportunity for the otherwise harmless C. glabrata to cause
candidiasis. As a result, C. glabrata is now second to C.
albicans among the various Candida species isolated from
patients with candidiasis [4, 5]. High prevalence of C.
glabrata in the oral flora of patients with diabetes mellitus,
advanced cancers, and HIV infection has been reported in
several studies [6–11]. Often, high mortalities are associated
with C. glabrata infections especially among cancer patients
and bone marrow transplant patients [12–16]. The majority
of C. glabrata isolates are reported to be resistant to both
fluconazole and itraconazole [11], whereas most isolates of
C. albicans are sensitive to these antifungal agents [9, 10].
Thus, it is even more important to diagnose C. glabrata
infections early and accurately so that the appropriate therapy
can be initiated [17, 18].
Although C. albicans and C. glabrata are often co-
isolated from mucosal lesions, not many investigations have
focused to study these organisms together. When together,
they exhibit more severe symptoms and pose a greater
difficulty in treatment [19, 20]. Molecular diagnostic
procedures described thus far to distinguish between these
two species cannot easily be incorporated as routine
diagnostics as they require specialized equipment and
expertise [21–25]. Although these organisms cannot be
distinguished based on the clinical presentation of the patients,
they differ in many aspects of genetic and physiological
attributes. C. albicans thrives as a diploid [26, 27] and
exhibits considerable heterozygosity while C. glabrata exists
as a haploid genome [28]. Unlike C. albicans, C. glabrata
cannot form true hyphae [29]. C. glabrata does not produce
extracellular proteinases including secreted aspartyl protei-
nases [30] which are considered as virulent factors of
Candida species [31–35]. C. albicans lacking superoxide
dismutases are unable to thrive in the presence of macro-
phages [36]. Phospholipases that have been implicated in the
virulence of C. albicans [37–41] also do not seem to play a
major role in C. glabrata infection [42, 43]. C. albicans and
C. glabrata are also known to differ in their host response
profiles. Infection by C. glabrata induces expression of high
levels of granulocyte monocyte colony-stimulating factor in
the cells of oral mucosa, while C. albicans is not known to
elicit such a response. On the other hand, C. albicans
infection produces a strong IL-8 response, whereas it is
elicited only weakly in the case of C. glabrata-infected cells
[44–46]. C. glabrata is often resistant to several antimicro-
bial proteins secreted by the host such as beta defensins [47–
49], histatins, and magainins [50–52]. A substantial variation
among gene families involved in cell wall formation,
transport, and sexual reproduction has been reported by
comparing genomes of different pathogenic species of
Candida and related yeasts [53]. Interestingly, a phylogenetic
comparison of sequenced yeast genomes showed that C.
glabrata belongs to “Saccharomyces clade” while most other
Candida species including C. albicans belong to “Candida
clade” [53]. The existence of distinct variation in diverse
clinical features indicates the probable differences in the
mechanisms of infection and adaptations to overcome host
defense mechanisms and antifungal drugs. The availability of
genome sequence information for both C. albicans [26] and
C. glabrata [28] now provides a scaffold for proteomic
investigations to understand distinct biological traits of these
organisms at the molecular level. A comparative proteomic
profile of C. albicans and C. glabrata should also provide
information on differentially expressed proteins in these
organisms that could serve as candidate molecules to distin-
guish these two species by protein-based tests such as ELISA.
We describe a quantitative proteomic investigation using
isobaric tag for relative and absolute quantitation (iTRAQ)
reagents and mass spectrometry to identify the differentially
expressed proteins in C. albicans and C. glabrata.
Materials and Methods
Culturing of C. albicans and C. glabrata
C. albicans (MTCC 1637) and C. glabrata (MTCC 6507)
cultures were obtained from the Microbial Type Culture
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Collection & Gene Bank resource in Chandigarh, India.
The cells were cultured in identical conditions in 2% YPD
broth at 30°C with shaking for 6 h. The cells were
harvested at the same density by centrifuging at 2,000×g
for 10 min, and pellets were washed using sterile distilled
water. Cell pellets were stored at −80°C until further
analysis.
iTRAQ Labeling and Strong Cation Exchange
Fractionation
Cell pellets were dissolved in 0.5% SDS and homogenized.
The samples were subsequently sonicated using ultra-
sonicator (Branson Ultrasonics) and centrifuged at
10,000×g for 10 min at 4°C. Clear supernatant was
collected in fresh vials. Protein estimation was carried out
using Lowry’s assay. Further, two samples were normalized
based on total protein amount. Normalization was verified
by SDS-PAGE. Protein samples were reduced, cysteine-
blocked, and digested with trypsin. iTRAQ (Applied
Biosystems Catalog No. 4352135) labeling of peptides
was carried out according to manufacturer’s protocol
essentially as described earlier [54]. Briefly, 80 μg of
protein extract from each sample was treated with 2 μl of
reducing agent (tris(2-carboxyethyl) phosphine) at 60°C for
1 h and alkylated with 1 μl of methyl methanethiosulfonate
(MMTS)) for 10 min at room temperature. Proteins were
then digested using sequencing grade trypsin (Promega)
(1:10) overnight at 37°C. Peptides in duplicate from C.
albicans sample were labeled using iTRAQ reagents
containing reporters 114 and 115 and peptides in duplicate
from C. glabrata sample were labeled using iTRAQ
reagents containing reporters 116 and 117 (Fig. 1). Labeling
was carried out for 2 h at room temperature. After labeling,
the peptides from the two samples were pooled and
fractionated using strong cation exchange chromatography
on Polysulfoethyl A column (PolyLC, Columbia, MD)
(100×2.1 mm, 5 μm particles with 300 Å pores) using an
LC Packing HPLC system connected to a Probot fraction
collector. Thirty SCX fractions were collected at a flow rate
of 0.2 ml/min using a 70-min gradient of KCl from 0 to
350 mM concentration in 10 mM potassium phosphate
buffer, 25% acetonitrile (pH 2.85). The fractions were dried
and reconstituted in 10 μl of 2% trifluoroacetic acid before
mass spectrometric analysis.
Mass Spectrometry and Data Analysis
Mass spectrometry analysis was carried out using a
reversed-phase liquid chromatography system (RP-LC)
interfaced with a quadrupole time-of-flight mass spectrom-
eter (QSTAR/Pulsar, Applied Biosystems). MS/MS data
was acquired by online analysis of peptides eluted using 5–
40% acetonitrile in 0.1% formic acid for 30 min with a flow
rate of 300 nl/min. The MS/MS spectra were acquired in a
data-dependent manner from m/z 350 to 1,200 Da targeting
three most abundant ions in every survey scan for MS/MS
with a dynamic exclusion time of 45 s. Twenty percent
higher collision energy was applied during MS/MS scan
with a charge state-dependent collision energy selection
criteria.
We created a custom protein database of non-redundant
protein sequences of C. albicans and C. glabrata by
combining ORFs of C. albicans from the Candida Genome
Database (http://candidagenome.org/), ORFs of C. glabrata
from databases of Genolevures (http://genolevures.org/
download.html), and protein sequences of these organisms
from NCBI RefSeq database. This customized database
contained 39,196 protein sequences with 28,152 protein
sequences from C. albicans and 11,044 from C. glabrata.
We used ProteinPilot software (V 3.0 Applied Biosystems)

















Reduction, alkylation and trypsin digestion
4- plex iTRAQ labeling of peptides
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Pool
Fig. 1 A schematic of quantitative proteomic characterization of C.
albicans and C. glabrata. After homogenization of cells, the proteins
were digested with trypsin. The resulting peptides from C. albicans
and C. glabrata were labeled with different iTRAQ reagents in a 4-
plex strategy and subsequently pooled. The peptide mixture was
analyzed by LC-MS/MS, and the proteins were identified by searching
the MS/MS spectra against the custom protein database and
quantitated using intensities of reporter ions
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Cytosolic NADP-specific isocitrate dehydrogenase Idp2 (C. albicans) 
Hypothetical protein CAGL0B04917g (C. glabrata)
Heat shock protein Hsp90 (C. albicans)
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Enolase Eno1 (C. albicans) 
Hypothetical protein CAGL0I02486g (C. glabrata)
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peptide identification and Pro Group algorithm for summa-
rizing proteins. Search parameters included iTRAQ labeling
at N-terminus and lysine residues, cysteine modification by
MMTS as fixed modifications, and trypsin as a protease.
Proteins identified with >95% confidence or Protscore >1.3
as determined by Pro Group algorithm were used for further
analysis. We used false discovery rate analysis by PSPEP
software that is in-built into ProteinPilot 3.0. The data
generated by LC-MS/MS analysis of 30 SCX fractions
were searched against the custom protein database, which
includes protein sequences that belong to C. albicans and
C. glabrata filtered from RefSeq, Candida Genome
Database and ORF database of Genolvures using Protein-
Pilot 3.0 software. Peptides identified in this study are
catalogued in Supplementary Table 1. A detected protein
threshold of 1.3 which corresponds to a confidence of 95%
was used in identification and quantitation of proteins.
Results and Discussion
In this study, we applied a quantitative proteomic approach
to identify differentially expressed proteins in C. albicans
and C. glabrata. Cell lysates of C. albicans and C. glabrata
Fig. 2 MS/MS spectra of representative shared peptides from
differentially expressed ortholog proteins. a Peptides CATITPDEAR
and NILGGTVFR belonging to cytosolic NADP-specific isocitrate
dehydrogenase Idp2 [C. albicans SC5314] and CAGL0B04917g [C.
glabrata CBS138], expressed higher in C. glabrata. b Peptides
GVVDSEDLPLNLSR and SPFLDALK belonging to heat shock
protein Hsp90 [C. albicans SC5314] and hypothetical protein
CAGL0L00495g [C. glabrata CBS138] expressed higher in C.
glabrata. c Peptides IGSEVYHNLK and YDLDFK belonging to
enolase Eno1 [C. albicans SC5314] and CAGL0I02486g [C.
glabrata CBS138], expressed higher in C. albicans. d Peptides
GVNLPGTDVDLPALSEK and VHMIFASFIR belonging to pyru-
vate kinase Cdc19 [C. albicans SC5314] and CAGL0E05610g [C.
glabrata CBS138], expressed higher in C. albicans. (Insets) Relative
intensity of reporter ions (m/z; C. albicans 114, 115 and C. glabrata








Phosphoglucose isomerase Pgl1 (C. albicans)

































































































































































































































































Fig. 3 Representative MS/MS spectra of peptides which are
uniquely identified in either C. albicans or C. glabrata. a Peptide
DAMFAGDHINTTEDR belongs to phosphoglucose isomerase Pgl1.
b Peptide AVVFDTNGGQLVYK belongs to immunogenic alcohol
dehydrogenase Adh1 of C. albicans. c Peptide GLEPLGSVALR
belongs to hypothetical proteins CAGL0I06600g. d Peptide
LPLVGGHEGAGVVVAK belongs to CAGL0J01441g of C. glab-
rata. (Insets) Relative intensity of reporter ions (m/z; C. albicans
114, 115 and C. glabrata 116, 117) from MS/MS fragmentation
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were labeled with iTRAQ reagents as shown in Fig. 1. We
prepared technical replicates by labeling peptides derived
from C. albicans with iTRAQ reagents giving rise to
reporter ions at m/z of 114 and 115 and C. glabrata derived
peptides with those yielding reporter ions at m/z of 116 and
117. From a total of 24,196 MS/MS spectra, using a
ProtScore >1.3 (95% confidence) cutoff, we identified 500
proteins among these organisms, 386 of which belonged to
Table 1 A partial list of proteins differentially expressed in Candida albicans
Gene
IDs












































6 3640691 Likely cytosolic ribosomal
protein Rps24
[C. albicans]
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C. albicans and 114 proteins belonged to C. glabrata
(Supplementary Tables 2 and 3). As tryptic peptide profile
was different for individual proteins among protein homo-
log pairs of these two species, the ProteinPilot 3.0 software
could not cluster most of protein orthologs as “pairs”. In
this study, it clustered only 24 protein orthologs among the
500 identified proteins belonging to both species. Thus,
quantitation data determined by the ProteinPilot 3.0
software were biologically relevant for only these 24
ortholog proteins. Therefore, we performed in-house bio-
informatics analysis to determine protein pairs and their
relative expression levels based on the relative expression
profile of common tryptic peptides as follows. For each
protein identified, we determined its counterpart in other
species under investigation using a reciprocal BLAST
analysis. We identified another set of 35 ortholog proteins
in addition to 24 ortholog proteins clustered by ProteinPilot
3.0. At least one common tryptic peptide was observed for
these 59 ortholog pairs identified in this study. We
calculated weighted average ratio for relative expression
level of peptides for these 59 protein pairs using the
formula used by ProteinPilot 3.0 software. The values of
reporter ion ratio 115:114 for all of these protein pairs were
found to be near 1 as expected with an average of 1.05±
Table 2 A partial list of proteins with higher levels of expression in Candida glabrata
Gene
IDs
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9 3647488 Mitochondrial NADP-specific
isocitrate dehydrogenase Idp1
[C. albicans]
2.36 CATITPDEAR, NILGGTVFR –
2887212 Hypothetical protein
CAGL0D00770g [C. glabrata]
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0.08. Also, values of (116:114)/(117:114) were also expected
to be near 1 and found with an average of 0.93±0.1. MS/MS
spectra of representative peptides belonging to four
differentially expressed protein pairs are given in Fig. 2.
The relative intensities of reporter ions from these spectra
are shown in the insets. As shown in the Fig. 2, reporter
ion intensities of individual common peptides belonging
to same ortholog protein pairs were found to be in
agreement with each other. Intensities of these reporter
ions among technical replicates were also found to be in
the same range. The mass spectrometry data generated in
this study has been submitted to Peptidome resource
(http://www.ncbi.nlm.nih.gov/pepdome).
Substantial differences exist between the genomes and
proteomes of C. albicans and C. glabrata, which influences
protein identification in these two species. C. albicans is
diploid with considerable heterozygosity, whereas C. glab-
rata thrives as a simple haploid. C. albicans has 12,015
genes encoded by its heterozygous diploid genome including
alleles as described by genome sequencing consortium [26,
27], whereas C. glabrata has only over 5,000 genes as
described by Dujon et al. [28]. It was also observed that the
proteome diversity of C. albicans is further enhanced by
ambiguous usage of CUG codon to randomly incorporate
either amino acid leucine or serine in the proteome, whereas
such codon alternation is not reported in C. glabrata [55–57].
This protein pair analysis identified several proteins which
are expressed only in either C. albicans or C. glabrata. MS/
MS spectra of these peptides showed only reporter ions
belonging to either C. albicans or C. glabrata (Fig. 3).
Proteins which are found to be expressed only in C. albicans
included 3-phosphoglycerate kinase (Pgk1), pyruvate decar-
boxylase (CaO19.2877), immunogenic alcohol dehydrogenase
(Adh1), and heat shock protein 60 (Hsp60). It is interesting to
note that several proteins involved in glucose metabolism
including gluconeogenesis are highly expressed in C. albi-
cans. There is also a marked difference in the expression of
serine-, lysyl-, leucyl-, and valyl-tRNA synthetases and
several ribosomal subunits, which is significant in the context
of differential usage of specific codons in C. albicans or C.
glabrata [53]. Proteins expressed unique to C. glabrata
included hypothetical proteins CAGL0I06600g (similar to
ubiquitin-specific proteinase Ubp3), CAGL0I01496g (simi-
lar to heat shock protein Ssc1), CAGL0E03916g (similar to
glycerol kinase Gut1), and CAGL0L12364g (similar to
acetyl-CoA C-acetyltransferaseYPL028w).
Analysis of expression levels of orthologous proteins
showed that 19 proteins of C. albicans were found to be
higher (>1.5-fold) in abundance when compared to their
corresponding orthologs in C. glabrata (Table 1). Conversely,
expression levels of 12 C. glabrata proteins were found to be
higher when compared to their counterparts in C. albicans
(Table 2). The relative protein expression ratios (i.e., 116:114
or 117:114) for the remaining 28 protein pairs ranged from
0.75 to 1.5 (Fig. 4). Proteins with higher expression levels in
C. albicans included enolase (Eno1), fructose-bisphosphate
aldolase (Fba1), dihydroxyacid dehydratase (Ilv3), glutathi-
one oxidoreductase (Glr1), ubiquitin-activating enzyme
(Uba1), and chaperonin CCT ring complex subunit (Cct2).
Interestingly, fructose-bisphosphate aldolase has already been
investigated as a target in C. albicans using a methionine/
cysteine-conditional mutant [58]. Proteins expressed higher in
C. glabrata include several hypothetical proteins
CAGL0F06941g (similar to pyruvate carboxylase fragment
Pyc2), CAGL0L00495g (similar to heat shock protein Hsp90),
CAGL0A00495g (similar to adenosine triphosphatase Pma1),
CAGL0L02321g (likely adenylylsulfate kinase Met14),
CAGL0B04917g (similar to cytosolic NADP-specific isoci-
327 59 55
Proteins from




 C. albicans and C. glabrata
which  share tryptic peptides
Proteins expressed higher in C. albicans
Proteins expressed higher in C. glabrata




Fig. 4 Proteins identified in C. albicans and C. glabrata. (Venn
diagram) Out of 500 proteins identified, shared tryptic peptides were
obtained for 59 protein orthologs. (Pie diagram) Based on relative
intensities of these shared peptides, abundances of these proteins
between two organisms were calculated. Out of 59 ortholog proteins,
19 were more abundant in C. albicans and 12 in C. glabrata
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trate dehydrogenase Idp2), and CAGL0D00770g (similar to
mitochondrial NADP-specific isocitrate dehydrogenase Idp1).
Overexpression of Hsp90 in C. glabrata is interesting in the
light of its established role in the emergence of azole drug
resistance. It was shown that loss of Hsp90 function in yeast
and C. albicans resulted in the decreased resistance to
antifungal drugs including echinocandins [59, 60].
The peptides/proteins which are unique to one organism
and/or differentially expressed between two organisms
should be attractive candidates as potential biomarkers for
the diagnosis and monitoring of treatment. Development of
similar rapid diagnostic methods have been investigated in
order to identify infections by Plasmodium falciparum,
Plasmodium vivax, Plasmodium ovale, and Plasmodium
malariae using antibodies generated against merozoite
surface protein 1, which are highly expressed among these
pathogens [61, 62]. Similarly, histidine-rich protein-2
(HRP-2) of P. falciparum and lactate dehydrogenase (Pv-
pLDH) of P. vivax have been targeted in the FK80 kit
(Standard Diagnostics, Korea) to differentially diagnose
malaria infection caused by P. falciparum and P. vivax [63].
Another successful attempt has been the development of
ELISA-based antigen capture assays targeting non-
structural protein (NS1) for laboratory detection of acute
primary and secondary dengue [61, 64, 65]. Our study
provides a list of proteins which are uniquely or differen-
tially expressed in C. albicans and C. glabrata which can
be used in the development of such diagnostic tests. This
study also demonstrates a comparative proteomics platform
which will facilitate the discovery of several such candidate
target molecules with diagnostic potential in many other
human diseases with multiple etiologies.
Conclusions
Generally, quantitative proteomic studies are carried out to
compare the proteomes of the same species under more than
one condition. Often, there is a need to compare two distinct
but related proteomes. The orthology-based approach has
been used to profile proteomes of organisms with unse-
quenced genomes [66], but not for differential profiling of
proteomes between two closely related organisms. Our study
outlines a strategy to investigate protein expression patterns
across closely related organisms, by combining orthology
information with quantitative proteomics. Such studies
should help identify mechanisms responsible for distinct
biological features of clinical importance among closely
related organisms as exemplified in C. albicans and C.
glabrata. As discussed previously, although C. albicans and
C. glabrata cause similar infections, they exhibit distinct
biological features. As most proteins from C. albicans and C.
glabrata are yet to be investigated in detail for their role in
various biological processes, our study provides the basis to
guide such investigations in the future.
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